Vaping Expected to Increase COPD Health and Economic Burden by 2050
ResMed presented 18 supported studies at ERS 2024, including research projecting the impact of vaping, smoking, and air pollution on COPD in Western Europe. Key findings include:
- 88.7 million new COPD hospitalizations projected across Western Europe between 2019-2050
- Vaping projected to incur almost €30 billion additional costs by 2050
- €4.9 trillion projected cumulative cost to support COPD lung conditions by 2050
- 16% projected reduction in risk of death after severe exacerbation for COPD patients using home NIV support
The research highlights the significant health and economic burden of COPD, exacerbated by environmental and behavioral factors. Home non-invasive ventilation (NIV) was found to reduce mortality risk in COPD patients.
ResMed ha presentato 18 studi supportati all'ERS 2024, inclusa la ricerca che proietta l'impatto di svapo, fumo e inquinamento atmosferico sulla BPCO in Europa occidentale. I risultati chiave includono:
- 88,7 milioni di nuove ospedalizzazioni per BPCO previste in tutta Europa occidentale tra il 2019 e il 2050
- Si prevede che lo svapo comporti quasi 30 miliardi di euro di costi aggiuntivi entro il 2050
- 4.9 trilioni di euro di costo cumulativo previsto per sostenere le condizioni polmonari della BPCO entro il 2050
- 16% di riduzione prevista nel rischio di morte dopo un'episodio acuto severo per i pazienti BPCO che utilizzano supporto NIV domiciliare
La ricerca evidenzia il significativo onere sanitario ed economico della BPCO, accentuato da fattori ambientali e comportamentali. È stato riscontrato che la ventilazione non invasiva domiciliare (NIV) riduce il rischio di mortalità nei pazienti con BPCO.
ResMed presentó 18 estudios respaldados en el ERS 2024, incluida la investigación que proyecta el impacto de vapear, fumar y la contaminación del aire en la EPOC en Europa Occidental. Las conclusiones clave incluyen:
- 88.7 millones de nuevas hospitalizaciones por EPOC proyectadas en toda Europa Occidental entre 2019 y 2050
- Se proyecta que el vapeo incurrirá en casi 30 mil millones de euros en costos adicionales para 2050
- 4.9 billones de euros en costos acumulativos proyectados para apoyar las condiciones pulmonares de EPOC para 2050
- 16% de reducción proyectada en el riesgo de muerte después de una exacerbación severa para los pacientes de EPOC que utilizan apoyo NIV en el hogar
La investigación destaca la carga significativa en salud y economía de la EPOC, agravada por factores ambientales y de comportamiento. Se encontró que la ventilación no invasiva en el hogar (NIV) reduce el riesgo de mortalidad en los pacientes con EPOC.
ResMed는 ERS 2024에서 18개의 지원 연구를 발표했습니다. 여기에는 서유럽에서 전자담배, 흡연 및 대기 오염이 COPD에 미치는 영향을 예측한 연구가 포함됩니다. 주요 결과는 다음과 같습니다:
- 2019-2050년 동안 서유럽에서 8,870만 건의 새로운 COPD 입원이 예상됨
- 전자담배는 2050년까지 약 300억 유로의 추가 비용을 초래할 것으로 보임
- 2050년까지 COPD 폐 질환을 지원하는 데 필요한 4.9조 유로의 누적 비용이 예상됨
- 자가 NIV 지원을 사용하는 COPD 환자에서 중증 악화 후 16%의 사망 위험 감소가 예상됨
이 연구는 환경적 및 행동적 요인에 의해 악화된 COPD의 건강 및 경제적 부담을 강조합니다. 자가 비침습적 환기(NIV)는 COPD 환자의 사망 위험을 줄이는 것으로 나타났습니다.
ResMed a présenté 18 études soutenues lors de l'ERS 2024, y compris des recherches projetant l'impact de vapotage, de tabagisme et de pollution de l'air sur la BPCO en Europe de l'Ouest. Les principales conclusions comprennent :
- 88,7 millions de nouvelles hospitalisations pour BPCO projetées en Europe de l'Ouest entre 2019 et 2050
- Le vapotage devrait engendrer près de 30 milliards d'euros de coûts supplémentaires d'ici 2050
- 4,9 billions d'euros de coûts cumulés projetés pour soutenir les conditions pulmonaires de BPCO d'ici 2050
- 16 % de réduction du risque de décès après une exacerbation sévère pour les patients BPCO utilisant un soutien NIV à domicile
La recherche met en évidence le fardeau économique et sanitaire significatif de la BPCO, aggravé par des facteurs environnementaux et comportementaux. La ventilation non invasive à domicile (NIV) a été identifiée comme réduisant le risque de mortalité chez les patients atteints de BPCO.
ResMed hat auf der ERS 2024 18 unterstützte Studien präsentiert, darunter auch Forschungen, die die Auswirkungen von Dampfen, Rauchen und Luftverschmutzung auf COPD in Westeuropa prognostizieren. Zu den wichtigsten Ergebnissen gehören:
- Voraussichtlich 88,7 Millionen neue Krankenhausaufenthalte wegen COPD in Westeuropa zwischen 2019 und 2050
- Vom Dampfen erhobene fast 30 Milliarden Euro zusätzliche Kosten bis 2050
- 4,9 Billionen Euro an voraussichtlichen kumulierten Kosten für die Unterstützung von COPD-Lungenkrankheiten bis 2050
- Voraussichtliche 16%ige Risikominderung für den Tod nach schweren Exazerbationen bei COPD-Patienten, die Unterstützung durch NIV zu Hause nutzen
Die Forschung hebt die erhebliche Gesundheits- und Kostenbelastung durch COPD hervor, die durch Umwelt- und Verhaltensfaktoren verschärft wird. Die häusliche nicht-invasive Beatmung (NIV) wurde als wirksam bei der Reduzierung des Sterberisikos bei COPD-Patienten festgestellt.
- ResMed-supported research presented at ERS 2024 provides valuable projections on COPD burden
- Home non-invasive ventilation (NIV) shown to reduce mortality risk in COPD patients by 16% following severe exacerbations
- Study involved nearly 50,000 adults with COPD treated via home NIV, providing robust data
- Vaping projected to incur almost €30 billion additional direct and indirect costs by 2050
- 88.7 million new COPD hospitalizations projected across Western Europe between 2019-2050
- Annual direct and indirect costs of COPD projected to reach over €170 billion by 2050
- Cumulative cost to support COPD lung conditions projected to reach €4.9 trillion by 2050
- Vaping expected to increase number of COPD exacerbations by 1.6 million cumulatively by 2050
This study projects a significant increase in COPD burden due to vaping, smoking and air pollution in Western Europe. Key findings include:
- 88.7 million new COPD hospitalizations projected by 2050
- Vaping alone expected to incur
€30 billion in additional costs €4.9 trillion cumulative cost for COPD support by 205016% reduction in mortality risk for COPD patients using home NIV
These projections highlight the urgent need for public health interventions targeting risk factors like vaping and air pollution. The potential economic impact is substantial, emphasizing the importance of preventive measures and early intervention strategies for COPD management.
The projected economic burden of COPD in Western Europe is alarming. By 2050, annual costs are expected to reach
- Increased investment in COPD prevention programs
- Development of cost-effective treatment strategies
- Policy measures to reduce vaping and improve air quality
The economic implications extend beyond healthcare, affecting productivity and overall economic growth. Policymakers and healthcare systems must prioritize COPD prevention and management to mitigate these projected costs.
This research highlights the growing public health crisis of COPD in Western Europe. Key concerns include:
- Vaping's emerging role in COPD burden, previously underestimated
- Projected
0.3% increase in exacerbations due to vaping (1.6 million cases) 0.2% increase in hospitalizations (190,000 cases) attributed to vaping- Positive impact of home NIV in reducing mortality risk
These findings call for urgent action in public health policy, including stricter regulation of vaping products, enhanced air quality measures and increased access to home NIV for COPD patients. Education campaigns on COPD risks and early symptom recognition are crucial. The projected burden necessitates a comprehensive, multi-faceted approach to COPD prevention and management.
New ResMed-supported research presented at ERS 2024 projects future Chronic Obstructive Pulmonary Disease (COPD) burden in Western Europe, accounting for increased air pollution, tobacco smoking, and vaping, with Non-Invasive Ventilation (NIV) enhancing survival rates.
- 88.7 million new COPD hospitalizations projected across Western Europe between 2019 - 2050
- Vaping projected to incur almost
€30 billion additional direct and indirect costs by 2050 €4.9 trillion projected cumulative cost to support COPD lung conditions by 205016% projected reduction in risk of death after a severe exacerbation for COPD patients using home NIV support
SAN DIEGO and VIENNA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ResMed presented 18 supported studies at ERS 2024, including research that projects vaping, smoking, and air pollution will substantially increase the economic and public health burden of COPD in Western Europe. Annual direct and indirect costs are projected to reach over
COPD poses a significant health and economic burden, further exacerbated by environmental and behavioral changes such as air pollution and vaping. Previous modeling work has focused on quantifying the burden of COPD across North America, accounting for tobacco smoking and air pollution1. The ResMed-supported research aimed to extend this US modeling by also accounting for the effects of vaping on the COPD burden in Western Europe2.
The results of this pertinent research were presented at ERS 2024 by Elroy Boers, PhD, Lead Health Research Scientist, ResMed. The model projected that, in addition to smoking and air pollution, vaping is going to have a notable economic and health impact on the burden of COPD into 2050, both cumulatively and annually.
2050 outcomes describing the relative increase associated with vaping (vs. the scenario without vaping) were concluded to be:
- Direct costs are projected to relatively increase by
0.5% (cumulative) and2.1% (annual) – representing a cumulative increase of€10 billion . - Indirect costs are projected to relatively increase by
0.7% (cumulative) and2.3% (annual) – representing a cumulative increase of€20 billion . - The number of exacerbations is estimated to relatively increase by
0.3% or 1.6 million (cumulative) and1.8% (annual) - The number of hospitalizations is projected to increase by
0.2% or 190,000 (cumulative) and3.3% (annual).
“To avoid escalating costs to public finances, additional strain on health services, and reduce loss of life from COPD, much greater action is required. Public health and advocacy efforts targeting known risk factors such as smoking, vaping, and ambient and household air pollution may be critical to prevent this anticipated burden,” said ResMed Chief Medical Officer Carlos M. Nunez, M.D.
In a separate ResMed-supported study presented by Professor Jean-Louis Pépin, Grenoble Alpes University, France, the role of home non-invasive Ventilation (NIV) support in managing COPD was explored. The study found that continued use of home NIV significantly reduces risk of death from COPD flare-ups (exacerbations), with a
“The positive impact of home NIV in reducing risk of death offers some comfort for those millions of people already suffering from COPD and those who will suffer in years to come. However, proactive work now on the part of potential patients and their loved ones to learn and recognize symptoms early, as well as preventative steps to reduce risk factors, will go a long way toward positively impacting hundreds of millions of lives worldwide,” Nunez continued. “Education and meaningful action are essential to curbing the number of people impacted by COPD and life-threatening events caused by these conditions.”
Complete list of ResMed-supported studies presented at ERS 2024:
- The modified Baveno classification for obstructive sleep apnoea management
- Impact of home NIV on severe exacerbations and survival in COPD: a French nationwide cohort study using multistate models
- Light, latitude and Epworth Sleepiness Scale in the European Sleep Apnea database - a daring proposal
- The economic and health burden of COPD in Western Europe through 2050: a scenario analysis based on two large data sources
- Role of Partnership in PAP Therapy Adoption in Obstructive Sleep Apnoea
- A negative effect by ATC N-class treatment in OSA patients with concomitant psychiatric disease: an ESADA cohort study.
- Association of sleep-related hypoxia with survival in patients with non-small cell lung cancer – the NEOSAS-GFPC study group
- Adaptive servo-ventilation (ASV) in patients with central or complex sleep apnea and associated cardiovascular comorbidities: the READ-ASV registry
- Effect of adaptive servo-ventilation on cardiac repolarization in patients with myocardial infarction and sleep-disordered breathing
- Effect of non-respiratory arousals on residual sleepiness in CPAP-treated OSA patients
- The association between behavioural clusters and short-term PAP usage in OSA
- PAP use in OSA patients with and without insomnia
- Usage of adaptive servo-ventilation (ASV): results from the READ-ASV registry
- A scenario-based modelling study to project the future burden of COPD in Western Europe accounting for air pollution, tobacco smoking, and e-cigarette vaping
- Obstructive Sleep Apnoea and C-reactive protein levels: Data from the ESADA
- Preserved ratio impaired spirometry and OSA may contribute to cardio-metabolic complications: evidence from the ESADA cohort
- Comparisons of cardiovascular risk scores in patients with obstructive sleep apnea - the European Sleep Apnea Database (ESADA)
- Effect of CPAP on circulating levels of MPO and MMP-9 in adults with coronary artery disease and obstructive sleep apnoea: the RICCADSA randomized controlled trial
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
For Media
Emily Yandle
ResMedUK@teamlewis.com
Julia Moser
news@resmed.com
1 E. Boers, A. Allen, A. Benjafield, M. Barrett, and A. Malhotra. The Economic and Health Burden of COPD in North America: Forecasting Through 2050 (abstract). Am J Respir Crit Care Med2023;207:A3593.
2 E. Boers, A. Allen, A. Benjafield, L.E. Crotty Alexander, A. Malhotra and M. Barrett. A scenario-based modeling study to project the future burden of COPD in Western Europe accounting for air pollution, tobacco smoking, and e-cigarette vaping. (abstract). ERS 2024.
FAQ
What is the projected economic impact of vaping on COPD in Western Europe by 2050?
How many new COPD hospitalizations are expected in Western Europe between 2019 and 2050?
What is the cumulative cost projected to support COPD lung conditions in Western Europe by 2050?
How does home non-invasive ventilation (NIV) affect mortality risk in COPD patients?
What factors are contributing to the increased COPD burden in Western Europe, according to the RMD research?
